Highest-materiality recent filing
Repligen closes BioLife acquisition; holders get $11.25 cash plus 0.1442 Repligen shares
Merger completed Oct 6, 2026 under the July 21, 2026 agreement; BioLife shareholders received $11.25 cash plus 0.1442 Repligen shares per share.
BioLife HSR waiting period expires for Repligen acquisition; vote set for Oct 5
HSR waiting period expired Sept 3, 2026, clearing antitrust condition for Repligen merger.
BioLife Q2 rev $28.5M (+21% YoY); GAAP net $45.1M incl $42.4M tax benefit; Repligen deal pending Q4
Total revenue $28.5M, up 21% YoY from $23.4M; GAAP gross margin 64%.
Repligen CEO sends video to BioLife employees; merger expected to close in Q4 2026
Repligen CEO Olivier Loeillot recorded video message for BioLife employees on August 3, 2026.
Repligen to acquire BioLife for $1.5B enterprise value, $31.00 per share
Repligen to acquire BioLife for $31.00/share (0.1442 RGEN shares + $11.25 cash); total enterprise value ~$1.5B.
Presentation dated June 3, 2026, furnished as Exhibit 99.1.
BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M
Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.
BioLife Solutions issues routine investor presentation; no material news disclosed
Investor presentation released on March 2, 2026, highlights cell-based therapy solutions.
BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M
Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).
Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.
Karen Foster, Chief Quality and Operations Officer, notified retirement effective March 31, 2026.
Filed an 8-K to furnish investor presentation dated November 17, 2025.
BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M
Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).
BioLife Solutions annual meeting: two directors face >40% withhold votes
All seven director nominees re-elected; Ellingson and Goswami each received >40% withhold votes (19.8M and 17.5M withheld, respectively).
BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M
Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).
BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M
Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.
BioLife appoints Cathy Coste to board as director and audit committee chair
Effective March 18, 2025, Catherine Coste appointed to board, replacing Joydeep Goswami as audit committee chair.
BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%
Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).
BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance
Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).
BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025
Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.
Sold Custom Biogenic Systems (CBS) to Standex International for ~$6.1M; transaction closed Nov 14, 2024.
BioLife Solutions sells SciSafe for $73M cash; closes Nov 12, 2024
Sold all SciSafe shares to Subzero Purchaser Corp. for $73M; repaid $0.9M of SciSafe debt and paid $3.3M to waive earn-out rights.
BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M
Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).
BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M
Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.
BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M
Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).
Roderick de Greef, Joydeep Goswami, Amy DuRoss, Rachel Ellingson, and Timothy Moore re-elected as directors.
BioLife Q1 net loss $10.2M; revenue down 16% YoY; divests GCI freezer unit, reaffirms 2024 guidance
Q1 total revenue $31.7M (-16% YoY); Cell Processing $16.2M (+10% seq), Biostorage $7.1M (+25% YoY), Freezers $8.4M (-35% YoY).
BioLife Solutions sells Global Cooling for $1, incurs ~$7.4M cash outflows
Sold Global Cooling for $1.00; provided $4.9M to meet $7M cash closing condition.
BioLife Solutions divests Stirling freezer business for $1; cuts 11% of workforce
Sold Global Cooling (Stirling) for $1.00; expects to eliminate several million dollars of quarterly cash burn.
BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive
Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.
BioLife Q4 preliminary revenue $32.7M, down 26% YoY; cell processing up 11% sequentially
Q4 2023 total preliminary unaudited revenue $32.7M, down 26% vs Q4 2022 ($44.3M).
BioLife Solutions Q3 revenue falls 18% YoY; net loss widens to $29.1M on $15.5M impairment
Total revenue $33.3M, down 18% YoY; ex-COVID revenue down 10%.
BioLife Solutions names Roderick de Greef CEO; prelim Q3 rev $33.3M, FY23 guidance at low end
Michael Rice resigns as CEO and Chairman; Roderick de Greef appointed President, CEO, and Chairman effective Oct 19, 2023.
BioLife Solutions: Casdin Partners ups stake to 19.5% with $10.4M private placement
Sold 927,165 new shares to Casdin Partners at $11.19/share, raising ~$10.4M.
BioLife Solutions issues investor presentation; no specific financial updates disclosed
Filed investor presentation dated August 2023 under Item 7.01 Regulation FD.
BioLife execs to receive up to 100% of base salary in stock through Dec 2023
CEO Michael Rice to receive 50% of base salary in vested shares for Aug 14-Dec 31, 2023; 50% in cash.
BioLife Q2 revenue falls 3% to $39.5M; net loss $0.23/share; cuts FY guidance; plans freezer divest
Q2 2023 revenue $39.5M, down 3% YoY; cell processing up 22% but freezers down 26%.
Re-elected all seven director nominees: Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss, Rachel Ellingson, Roderick de Greef, and Timothy Moore.
BioLife Solutions amends severance for CFO and SVP; increases to 12 months
CFO Troy Wichterman severance increased from 9 to 12 months base salary plus COBRA.
BioLife Solutions sets 2023 annual meeting for July 21; new proposal deadline June 6
Annual meeting will be held virtually on July 21, 2023, per company's definitive proxy statement.
BioLife Solutions Q1 revenue up 4% to $37.7M; net loss widens, explores sale of freezer lines
Revenue $37.7M (+4% YoY); ex-COVID growth 16%; biopreservation media revenue +28%.
Analyst Day held on March 23, 2023; corporate presentation posted on company website.
BioLife Solutions FY2022 revenue $161.8M (+36% YoY); GAAP net loss $139.8M on $110.4M impairment
Full year 2022 revenue $161.8M, up 36% vs 2021; biopreservation media revenue grew 45%.
GAAP net loss of $10.0M ($0.23 loss per share) vs net income of $79K in Q3 2021.
BioLife Solutions COO de Greef to retire, appointed to Board; Phillips promoted to SVP Global Ops
Roderick de Greef, President & COO, to retire from management effective Jan 3, 2023; will join the Board of Directors.
BioLife Solutions enters up to $40M term loan facility with Silicon Valley Bank
Term loans up to $40M total; $10M conditional on achieving revenue milestones by June 30, 2023.
BioLife Solutions appoints Timothy L. Moore to board of directors effective Sept 1, 2022
Moore brings 30+ years biopharma ops experience; served as EVP Technical Ops at Kite Pharma (Gilead) and head of Genentech biologics ops.
BioLife Q2 rev $40.5M (+30% YoY); net loss $72.6M on $69.9M impairment; guides FY22 rev $160-166M
Q2 2022 revenue $40.5M, up 30% YoY; organic growth 44%; biopreservation media revenue up 46%.
BioLife Solutions stockholders re-elect all directors, approve equity plan increase
All five nominees re-elected: Michael Rice (26.8M for), Joydeep Goswami (26.5M), Joseph Schick (21.9M), Amy DuRoss (26.0M), Rachel Ellingson (26.3M).
BioLife Solutions Q1 revenue $36.2M (+115% YoY); net loss $7.1M vs $1.1M
GAAP EPS -$0.17 vs -$0.03; adjusted EBITDA -$814K vs +$2.8M a year ago.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Effective as of the First Merger Effective Time, each of Roderick de Greef, Troy Wichterman, Aby J. Mathew, Todd Berard and Sean Warner, comprising all of BioLife’s named executive officers, resigned from their respective positions with BioLife.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Effective as of the First Merger Effective Time, each of Roderick de Greef, Troy Wichterman, Aby J. Mathew, Todd Berard and Sean Warner, comprising all of BioLife’s named executive officers, resigned from their respective positions with BioLife.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Effective as of the First Merger Effective Time, each of Roderick de Greef, Troy Wichterman, Aby J. Mathew, Todd Berard and Sean Warner, comprising all of BioLife’s named executive officers, resigned from their respective positions with BioLife.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Effective as of the First Merger Effective Time, each of Roderick de Greef, Troy Wichterman, Aby J. Mathew, Todd Berard and Sean Warner, comprising all of BioLife’s named executive officers, resigned from their respective positions with BioLife.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the First Merger Effective Time, each of Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt and Tim Moore, comprising all of the members of BioLife’s board of directors, ceased serving as a member of BioLife’s board of directors and each committee thereof.
Effective as of the First Merger Effective Time, each of Roderick de Greef, Troy Wichterman, Aby J. Mathew, Todd Berard and Sean Warner, comprising all of BioLife’s named executive officers, resigned from their respective positions with BioLife.
Max materiality 1.00 · Median 0.65 · Most common event earnings